Microsoft Excel LibreOffice Calc

Eli Lilly & Co. (NYSE:LLY)


Analysis of Liquidity Ratios

Beginner level


Liquidity Ratios (Summary)

Eli Lilly & Co., liquidity ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Current ratio 1.16 1.73 1.32 1.37 1.53
Quick ratio 0.68 1.20 0.91 0.98 1.04
Cash ratio 0.21 0.68 0.55 0.55 0.54

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Eli Lilly & Co.’s current ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Eli Lilly & Co.’s quick ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Eli Lilly & Co.’s cash ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.

Current Ratio

Eli Lilly & Co., current ratio calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Current assets 13,709,600  20,549,600  19,202,100  15,101,400  12,573,600 
Current liabilities 11,775,200  11,888,100  14,535,900  10,986,600  8,229,600 
Liquidity Ratio
Current ratio1 1.16 1.73 1.32 1.37 1.53
Benchmarks
Current Ratio, Competitors2
Abbott Laboratories 1.44 1.62 2.26 4.02 1.54
AbbVie Inc. 3.18 0.98 1.28 1.65 1.50
Allergan PLC 1.01 1.13 1.16 2.27 1.03
Amgen Inc. 1.44 2.79 5.49 4.11 4.44
Biogen Inc. 1.72 2.32 2.34 2.55 2.60
Bristol-Myers Squibb Co. 1.60 1.61 1.55 1.55 1.30
Gilead Sciences Inc. 3.10 3.38 2.74 2.22 2.50
Johnson & Johnson 1.26 1.47 1.41 2.47 2.17
Merck & Co. Inc. 1.24 1.17 1.33 1.78 1.55
Pfizer Inc. 0.88 1.57 1.35 1.25 1.49
Regeneron Pharmaceuticals Inc. 3.67 4.47 3.82 2.56 3.59
Vertex Pharmaceuticals Inc. 3.61 3.43 3.28 2.31 2.78
Zoetis Inc. 2.63 3.60 3.85 3.03 2.15
Current Ratio, Sector
Pharmaceuticals & Biotechnology 1.53 1.72 1.78 2.11 1.89
Current Ratio, Industry
Health Care 1.40 1.51 1.60 1.80 1.70

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

1 2019 Calculation
Current ratio = Current assets ÷ Current liabilities
= 13,709,600 ÷ 11,775,200 = 1.16

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Eli Lilly & Co.’s current ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.

Quick Ratio

Eli Lilly & Co., quick ratio calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 2,337,500  7,998,200  6,536,200  4,582,100  3,666,400 
Short-term investments 101,000  88,200  1,497,900  1,456,500  785,400 
Accounts receivable, net of allowances 4,547,300  5,246,500  4,546,300  4,029,400  3,513,000 
Other receivables 994,200  958,400  715,900  736,900  558,600 
Total quick assets 7,980,000  14,291,300  13,296,300  10,804,900  8,523,400 
 
Current liabilities 11,775,200  11,888,100  14,535,900  10,986,600  8,229,600 
Liquidity Ratio
Quick ratio1 0.68 1.20 0.91 0.98 1.04
Benchmarks
Quick Ratio, Competitors2
Abbott Laboratories 0.88 1.03 1.67 3.31 1.04
AbbVie Inc. 2.91 0.78 0.89 1.14 1.21
Allergan PLC 0.82 0.83 0.95 2.00 0.42
Amgen Inc. 1.01 2.44 4.98 3.68 3.97
Biogen Inc. 1.43 1.83 1.78 1.94 1.93
Bristol-Myers Squibb Co. 1.26 1.37 1.30 1.27 1.05
Gilead Sciences Inc. 2.86 3.15 2.52 1.78 2.07
Johnson & Johnson 0.94 1.08 1.04 2.04 1.77
Merck & Co. Inc. 0.78 0.72 0.83 1.24 1.04
Pfizer Inc. 0.50 0.84 0.93 0.84 1.07
Regeneron Pharmaceuticals Inc. 2.81 3.50 2.98 2.13 3.10
Vertex Pharmaceuticals Inc. 3.33 3.19 2.94 2.06 2.41
Zoetis Inc. 1.67 2.24 2.34 1.47 1.17
Quick Ratio, Sector
Pharmaceuticals & Biotechnology 1.15 1.27 1.38 1.66 1.44
Quick Ratio, Industry
Health Care 1.04 1.11 1.23 1.40 1.30

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

1 2019 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 7,980,000 ÷ 11,775,200 = 0.68

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Eli Lilly & Co.’s quick ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.

Cash Ratio

Eli Lilly & Co., cash ratio calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 2,337,500  7,998,200  6,536,200  4,582,100  3,666,400 
Short-term investments 101,000  88,200  1,497,900  1,456,500  785,400 
Total cash assets 2,438,500  8,086,400  8,034,100  6,038,600  4,451,800 
 
Current liabilities 11,775,200  11,888,100  14,535,900  10,986,600  8,229,600 
Liquidity Ratio
Cash ratio1 0.21 0.68 0.55 0.55 0.54
Benchmarks
Cash Ratio, Competitors2
Abbott Laboratories 0.38 0.45 1.08 2.82 0.67
AbbVie Inc. 2.56 0.47 0.59 0.66 0.77
Allergan PLC 0.53 0.33 0.65 1.68 0.13
Amgen Inc. 0.69 2.17 4.62 3.40 3.62
Biogen Inc. 0.92 1.07 1.10 1.43 1.33
Bristol-Myers Squibb Co. 0.84 0.83 0.71 0.72 0.53
Gilead Sciences Inc. 2.50 2.84 2.19 1.29 1.48
Johnson & Johnson 0.54 0.63 0.60 1.59 1.38
Merck & Co. Inc. 0.47 0.40 0.46 0.83 0.70
Pfizer Inc. 0.26 0.59 0.66 0.57 0.79
Regeneron Pharmaceuticals Inc. 1.53 1.95 1.24 0.84 1.29
Vertex Pharmaceuticals Inc. 2.85 2.83 2.59 1.81 2.06
Zoetis Inc. 1.07 1.39 1.43 0.65 0.65
Cash Ratio, Sector
Pharmaceuticals & Biotechnology 0.79 0.87 0.98 1.26 1.05
Cash Ratio, Industry
Health Care 0.66 0.71 0.85 0.99 0.91

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

1 2019 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 2,438,500 ÷ 11,775,200 = 0.21

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Eli Lilly & Co.’s cash ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.